Inhibition by bestatin of a mouse ascites tumor dipeptidase. Reversal by certain substrates.
Bestatin, [(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]-L-leucine, a known inhibitor of aminopeptidases, is shown to be a potent linear competitive inhibitor (KI,2.7 nM) of a dipeptidase purified from Ehrlich-Lettré hyperdiploid mouse ascites tumor cells. This inhibition can be classified as "slow binding" but not as "tight binding." Substrate protects the enzyme from bestatin inhibition when enzyme and inhibitor are in approximately equimolar concentrations. Addition of substrate (6 mM) partially (by about 20%) reverses dipeptidase inhibition by bestatin, but the time required for maximum recovery depends on the nature of the substrate. Substrates with lower Km (0.28-1.4 mM) values that exhibit substantial substrate inhibition require longer times (23-65 min) than those with higher Km values that show little substrate inhibition. Substrates with Km values higher than 1.5 mM do not reverse inhibition. The inhibition of the tumor dipeptidase by bestatin has been compared with inhibition by a variety of inhibitors of other Zn-metallo-proteolytic enzymes. These inhibitors were far less potent (KI, 0.063-10 mM), indicating a difference between the tumor dipeptidase and other enzymes of that class. Our results are discussed in terms of a postulated model of the bestatin molecule in the active site of the tumor dipeptidase, an enzyme which has not been studied by x-ray crystallographic means. The phenyl group of bestatin is placed in a hydrophobic pocket that is external but adjacent to the active site of the tumor dipeptidase. The shape of this pocket, as it appears from our results plus modeling, is such that only certain R groups of substrate can fit. The existence of such a pocket might explain the differential effect of substrates in the reversal of bestatin inhibition of the dipeptidase and also might explain substrate inhibition by misalignment of R groups into this pocket.
Patterson
E K
EK
Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology*; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D004151:Dipeptides / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D051379:Mice; D015394:Molecular Structure; D009842:Oligopeptides / Q000494:pharmacology; D013329:Structure-Activity Relationship; D015032:Zinc
D004151:Dipeptides; D009842:Oligopeptides; C028872:alanylglycine; D004150:Dipeptidases; C038937:dipeptidase; D008666:Metalloendopeptidases; D007930:Leucine; C012211:ubenimex; D015032:Zinc